Dr. Dana Bar-On (course director) is the head of the industry-academia cooperation at the Sagol School of Neuroscience in Tel Aviv University. Tel Aviv University's Sagol School of Neuroscience is a center for excellence in Neuroscience research and education (http://neuroscience-web.tau.ac.il/en/). The school's community is composed of over 120 research groups led by internationally well-recognized scientists, coming from 7 different faculties and 17 medical centers affiliated with Tel Aviv University and Over 350 undergraduate and graduate students. As part of the School's philosophy, Dr. Bar-On initiated "BrainBoost", a unique framework for bridging the gap between the industry and academy and for advancing translational Neuroscience.
Dr. Bar-On is a researcher in Tel Aviv University focusing on developing early biomarkers for Parkinson's disease. She finished her Ph.D in Neurobiology focusing on super-resolution microscopy of synaptic proteins, and her B.Sc and M.Sc in distinction in Biotechnology at Tel Aviv University. Dr. Bar-On served as a scientific consultant at leading financial and high-tech private firms.
Dr Eyal Bressler is both a patent attorney and an attorney at law (IL) with more than twenty years of experience in drafting patents for, prosecution of and litigation of intellectual property rights in industries including medical devices, pharmaceuticals, computers, neuroscience, and deep learning.
Dr Bressler heads an IP firm comprising 35 attorneys and experts. The firm serves international companies, including Microsoft, Facebook, Syngenta, Gilead Sciences, Dior and Porches; the main universities in Israel, including the Weizmann Institute of Science, the Hebrew University, and the Volcani center for agricultural research; as well as many Israel-based companies and start-ups. In the last two years, the value of clients' IP commercialized by Dr Bressler's IP firm was about 0.9 billion dollars.
Dr Bressler holds a PhD in Biotechnology and an LLB in Law. He teaches the course "Innovation and IP" at Tel Aviv University, the Hebrew University and other institutes. He is a director and COB in various Med-Tech startups. Dr Bressler is an active member in AIPPI (Treasurer of AIPPI-IL), IAPA, LES, INTA, EFCCA and CCFI.
Tanja Rosenmund studied Biology at the University Heidelberg. She performed her PhD on "the role of Rab 5 in synaptic vesicle recycling" in the department of Prof. Herbert Jäckle in the laboratory of Dr. Marcos Gonzalez-Gaitan at the Max-Planck-Institute for Biophysical Chemistry and the Max-Planck-Institute for Molecular Cell Biology and Genetics in Dresden. She received her PhD from the University Kassel in 2002. After a postdoc in the laboratory of Prof Stefan Hell on high resolution imaging in exocytosis, she moved to Houston Texas. There, she continued her scientific work on synaptic vesicle exocytosis in the laboratory of Prof. Hugo Bellen. After moving to Berlin 2009 she worked as lab manager and postdoc in the laboratory of Prof. Christian Rosenmund with a strong focus on neurophysiology. Since 2015 Tanja Rosenmund is program coordinator of SPARK-Berlin (http://www.spark-berlin.org).
Konstantin Sonkin is a Research Fellow and Project Manager experienced in leading and handling projects in interdisciplinary areas, such as brain-computer interaction and artificial intelligence. Research and Development focus: development and implementation of high quality human-computer interaction system on the basis of advanced methods of artificial intelligence, which will be used worldwide, making a significant contribution to rehabilitation of immobilized people and to deeper understanding of brain activity. Research interests include artificial intelligence, machine learning, neuroscience, brain-computer interfaces, human-computer interaction.
Prof. Yesha Sivan is the Executive Director of The Coller Institute of Venture at Tel Aviv University faculty of management, and a visiting professor of innovation and venture at the Hong Kong Polytechnic University (PolyU), Design School.
He is also the founder of Metaverse Labs (MVL) - a leading think tank focusing on innovation via virtual and real worlds. Sivan's professional experience includes developing and deploying innovative solutions for corporate, hi-tech, government, and defense environments (see for example: the Harvard 9-Keys for Knowledge Infrastructure).
He published numerous papers in the areas of strategy and IT, innovation and venture, knowledge, 3D3C virtual worlds, and standards.
Sivan received his doctorate from Harvard University. He has taught EMBA, MBA, engineering and design courses in his areas of expertise. His blog is http://www.dryesha.com.
Christian Tidona is a serial biotech entrepreneur and managing director at BioRN Cluster Management GmbH and BioRN Network e.V. in Heidelberg, Germany. He studied biology at the University of Heidelberg and received his PhD in 1999 at the age of 28. After several years of experience as a founder, managing director and coach of a number of biotech companies such as Multimetrix (Regensburg), Microbionix (Neuried), Cytonet (Weinheim/Durham NC) and Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), he was important in the development of a new economic growth strategy for the Biotech Cluster Rhine-Neckar (BioRN), one of the leading life science clusters in Europe. Based on this strategy, the BioRN cluster was distinguished as one of the five most significant high-tech regions in Germany (Leading Edge Cluster Competition). It was awarded a 40 million Euro grant from the Federal Ministry for Education and Research (BMBF), which is now being used under Dr. Tidona's leadership together with another 40 million Euro from the local pharma and biotech industry for the implementation of the new growth strategy. Among other personal commitments, Dr. Tidona is a member of the executive board of the Health Axis Europe alliance between the three health clusters in Cambridge / UK, Leuven / Belgium and Heidelberg / Germany, member of the German-Israeli Life Sciences Committee, board member of the BioRN.
Irena Vertkin did her Ph.D thesis under supervision of Prof. Inna Slutsky studying molecular mechanisms of memory. As well, she worked for a number of years in biotechnology company Proneuron, where they worked on developing treatments for spinal cord injury and stroke. In her previous research, they usually used animal models and she is very excited by the opportunity to contribute to the development of human cells based models for neurological diseases working with Prof. Dalit Ben Yosef.